Skip to main content
Novartis
language-selector-globe
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Global | English
Novartis Foundation | English(link is external)
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English(link is external)
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 

      Team meeting
      About

      Every day, we work to reimagine medicine to improve and extend people’s lives. Learn about us and our story.

      • Novartis in the US 
      • People and culture 
      • Products 
      • Therapeutic areas 

        • Oncology 
      • Inclusion and belonging 
      • Manufacturing 
      • Contact us 
    • Patients and caregivers 

      • Novartis commitment to patients and caregivers 
      • Patient assistance 
      • Diseases 

        • Chronic spontaneous urticaria (CSU) 
        • Hidradenitis suppurativa (HS) 
        • Prostate Cancer (PC) 
        • Paroxysmal Nocturnal Hemoglobinuria (PNH) 
        • Breast Cancer 
        • Sjögren's Disease 
      • Participating in clinical trials 
      • Adverse event reporting 
      • Patient resources 
      Patient smiling at doctor image
      Patients and caregivers

      Visit resources tailored for our patient communities and their caregivers, including information around patient assistance, disease information and related resources.

    • Healthcare professionals 

      • Novartis pipeline 
      • Novartis clinical trials 
      • Adverse event reporting 
      • External funding 
      • HCP resources 
      • Personalized and Precision Medicine 
      • Health Information Technology Resources 
      Two doctors examining X-ray
      Healthcare professionals

      Visit our resource hub for information around clinical trials, our products and innovation pipeline.

    • ESG 

      • Ethical behavior 

        • Code of ethics 
        • SpeakUp 
        • PhRMA Code on interactions with healthcare professionals 
        • Business principles 
      • Ethics, risk and compliance 

        • Pay transparency-EPIC 
        • Compliance program 
        • State laws 
        • Corporate integrity agreement 
        • Payments to HCPs & HCOs 
        • Drug Supply Chain Security Act Information 
      • Corporate responsibility 

        • Novartis in Society Integrated Report 
        • Novartis US Foundation 
        • People and communities 
        • Beacon of hope 

      • Environmental sustainability 
      Family and friends party at home
      ESG

      Learn about our commitment to making a positive impact on society through innovative medicine access, sustainability, and governance.

    • News 

      • News archive 
      • Statements 
      • Stories 
      • Contacts 
      Co-workers having a meeting
      News

      Check out our media hub for the latest news, stories, and updates from across our business.

    • Careers 

      • Career search 
      • Early career 
      • Employee benefits 
      • Inclusion and belonging  
      Colleagues laughing
      Careers

      Check out what careers are available at Novartis in the U.S. and learn about our people and culture.

    Grandmother, mother and daughter smiling and laughing on a beach
    Home

    Working together, we can reimagine medicine to improve and extend people’s lives.

Header
Research scientist in a lab looking at a sample

Novartis United States

Working together, we can reimagine medicine

time 100 health

Exploring the future of cancer care

Novartis US President, Victor Bultó, offered insights into the changing oncology landscape at the Time 100 Health Impact Dinner.

Read more
Scientist in lab

Discover our medicines

See how our innovative medicines are addressing society's greatest health challenges.

Doctor and patient talking in hallway

Commitment to patients

From research and development to expanding access, uncover our commitment to improving people's lives.

business people meeting around a table image_0

Inspired by purpose

Learn about our people and culture, and how we're driven by our mission to reimagine medicine.

Q1 2025

Novartis Financial Results - Q1 2025

Novartis announced the company’s financial results for the first quarter of 2025.

Learn more

Latest News

May 15, 2025

  • Media Release

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline

Apr 10, 2025

  • Media Release

Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years

Apr 02, 2025

  • Media Release

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Read all news
Scientist with microscope

Welcome to where we thrive

Discover how you can join us in our mission to change people's lives.

Join us

Resource links

About Novartis
Commitment to patient and caregivers
Healthcare professional resources
Products
Pipeline
Contact us

Novartis United States

Navigate Novartis
  • Patients & caregivers
  • Healthcare professionals
  • ESG
  • News
  • Careers
Media center
  • News archive
  • Statements
  • Stories
Our portfolio
  • Novartis clinical pipeline
  • Novartis product portfolio
Other Novartis US websites
  • Oncology HCP resources
  • Medical information(link is external)
  • Global site
  • (link is external)
  • (link is external)
  • (link is external)
  • (link is external)
  • (link is external)
Footer Bottom
© 2025 Novartis Pharmaceuticals Corporation
  • Terms of use
  • Privacy policy
  • Consumer health privacy policy
  • Contacts
  • Site map
  • Web accessibility
Novartis Site Directory
This site is intended for US residents only